Oncology is a dynamic and diverse market. In 2017, oncology is estimated to lead all therapeutic areas in medicine spending (excluding supportive care) by developed nations, with revenues of $74–$84 billion. In pharmerging nations, it will to be the fourth-largest area, with $17–$20 billion in revenues. In 2013, global sales of oncology drugs totaled $37.2 billion. By treatment modality, targeted therapies, supportive care, cytotoxics and hormonals accounted for 46%, 24%, 20% and 10% of the world oncology market, respectively. The number of active products for oncology in the drug pipeline is 1,865, with 33% in preclinical development, 33% in Phase I, 26% in Phase II, 23% in Phase III and 9% in Pre-reg/Registered. More than 50% in each phase are biologics. In BRIC countries, 134 oncology products are in the drug pipeline. Biologics accounted for 47% of the global oncology market last year. Oncology biosimilars are estimated to make up 2%–5% of the biologics market in 2020, depending on the development of the US market.

Source: IMS Institute for Healthcare Informatics